Encompass Health Corp EHC

Healthcare SIC 8060 - Services-Hospitals NAICS Health Care and Social Assistance › Hospitals derived NYSE

We are the nation's largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment, using advanced technology and intensive therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence and quality of life. We operate hospitals in 39 states and Puerto Rico, with concentrations in Florida and Texas. As of December 31, 2025, we operated 173 inpatient rehabilitation hospitals. We are committed to delivering high-quality, cost-effective patient care. For 2025, we were named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista and ranked among Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America.

Last close 124.09 2026-10-23
Market cap $12.24B 2026-06-30 share count
52-week range 92.77 - 129.96

Valuation FY2025 figures against the last close

P/S2.1x
P/E22.4x
P/FCF27.9x
EV/EBITDA—
Dividend yield0.6%
Diluted EPS5.54

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $5.94B$5.37B$4.80B$4.35B$4.01B$3.57B$4.61B$4.28B$3.91B$3.64B
SG&A $236.2M$209.2M$201.7M$154.3M$169.5M$151.6M$247.0M$220.2M$171.7M$133.4M
Total operating expenses $4.88B$4.51B$4.07B$3.72B$3.36B$3.04B$3.91B$3.65B$3.26B$2.99B
Operating income ———$539.5M$559.6M$563.9M$612.1M$555.2M$578.3M$588.1M
Interest expense $123.2M$137.4M$143.5M$175.7M$164.3M$183.7M$159.7M$147.3M$154.4M$172.1M
Pre-tax income $953.0M$749.6M$607.2M$450.8M$505.0M$352.9M$562.3M$493.2M$496.4M$482.0M
Income tax $192.9M$150.2M$132.2M$100.1M$101.9M$74.7M$115.9M$118.9M$145.8M$163.9M
Net income $759.1M$596.6M$463.0M$365.9M$517.2M$284.2M$358.7M$292.3M$271.1M$247.6M
EPS, basic 5.624.533.512.724.152.873.652.982.882.77
EPS, diluted 5.544.463.472.704.112.853.612.932.842.59
Shares, diluted (wtd. avg.) 102.2M102.2M101.3M100.4M100.2M99.8M99.4M99.8M99.3M99.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $72.2M$85.4M$69.1M$21.8M$49.4M$185.6M$60.0M$69.2M$54.4M$40.5M
Receivables $613.4M$593.0M$599.8M$524.8M$502.1M$563.0M$498.7M$459.9M$459.5M$432.0M
Total current assets $905.9M$886.9M$841.8M$717.2M$921.4M$948.6M$755.8M$662.1M$702.2M$654.5M
Property, plant and equipment ——————$1.96B$1.63B$1.52B$1.39B
Goodwill $1.32B$1.28B$1.28B$1.26B$1.24B$1.23B$1.22B$2.10B$1.97B$1.93B
Other intangibles $308.3M$297.8M$278.2M$282.3M$158.4M$431.3M$476.3M$443.4M$403.1M$411.3M
Total assets $7.09B$6.53B$6.10B$5.64B$6.86B$6.45B$6.08B$5.17B$4.86B$4.68B
Accounts payable $178.2M$171.0M$170.0M$132.9M$134.0M$115.0M$94.6M$90.0M$78.4M$68.3M
Total current liabilities $836.4M$841.0M$656.4M$575.9M$748.8M$717.3M$721.0M$672.5M$517.5M$475.6M
Total liabilities $3.81B$3.69B$3.81B$3.77B$4.47B$4.44B$4.15B$3.36B$3.25B$3.61B
Retained earnings $1.29B$796.7M$406.5M$115.7M$141.8M-$242.3M-$526.5M-$885.2M-$1.18B-$1.45B
Total equity $2.44B$2.07B$2.26B$1.83B$2.36B$1.97B$1.69B$1.56B$1.40B$910.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.18B$1.00B$850.8M$705.8M$715.8M$704.7M$635.3M$762.4M$658.3M$640.2M
Depreciation and amortisation $327.9M$299.6M$273.9M$243.6M$219.6M$203.0M$218.7M$199.7M$183.8M$172.6M
Stock-based compensation $56.5M$48.3M$50.6M$29.2M$29.1M$25.6M$114.4M$85.9M$47.7M$27.4M
Capital expenditure $736.4M$642.5M$583.1M$584.1M$545.7M$392.8M$372.4M$254.5M$225.8M$177.7M
Investing cash flow -$764.6M-$653.3M-$602.8M-$627.0M-$666.3M-$407.5M-$657.4M-$424.5M-$283.0M-$229.9M
Financing cash flow -$431.2M-$330.6M-$197.2M-$145.7M-$240.1M-$145.9M$48.2M-$321.2M-$359.9M-$416.4M
Dividends paid $71.1M$62.8M$60.4M$99.0M$112.2M$111.8M$108.7M$100.8M$91.5M$83.8M
Buybacks $158.0M$31.1M$0$0$0$6.1M$45.9M$0$38.1M$65.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000785161-26-000105.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 2B 4B 6B Revenue, FY2016: 3.6B Net income, FY2016: 247.6M Revenue, FY2017: 3.9B Net income, FY2017: 271.1M Revenue, FY2018: 4.3B Net income, FY2018: 292.3M Revenue, FY2019: 4.6B Net income, FY2019: 358.7M Revenue, FY2020: 3.6B Net income, FY2020: 284.2M Revenue, FY2021: 4B Net income, FY2021: 517.2M Revenue, FY2022: 4.3B Net income, FY2022: 365.9M Revenue, FY2023: 4.8B Net income, FY2023: 463M Revenue, FY2024: 5.4B Net income, FY2024: 596.6M Revenue, FY2025: 5.9B Net income, FY2025: 759.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $3.64B $3.91B $4.28B $4.61B $3.57B $4.01B $4.35B $4.80B $5.37B $5.94B
Gross profit — — — — — — — — — —
Net income $247.6M $271.1M $292.3M $358.7M $284.2M $517.2M $365.9M $463.0M $596.6M $759.1M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Material agreement signed Item 1.01
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Material agreement signed Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8060

TickerCompanyMarket capP/ERevenue growth
MD Pediatrix Medical Group, Inc. $2.38B 15.1x -4.9%